Physician profile
Stratego Castanes
NPI 1427082114
$5,550.93
in general payments reported to CMS, 2019-2025
27 companies · $543 in 2025
The $543 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,061 · 2020: $840 · 2021: $1,066 · 2022: $719 · 2023: $615 · 2024: $707 · 2025: $543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,865.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,864.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,043.13 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $765.64 | 2019-2025 | |
| Amarin Pharma, INC. | $747.91 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $396.08 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $372.24 | 2019-2025 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $338.48 | 2019-2025 | |
| Esperion Therapeutics, INC. | $323.93 | 2020-2025 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $248.35 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $218.63 | 2022-2025 | Verquvo, Capvaxive |
| Impulse Dynamics (USA) INC. | $148.21 | 2021-2024 | Optimizer, Optimizer |
| Abbvie INC. | $130.12 | 2024 | |
| Azurity Pharmaceuticals, INC. | $129.63 | 2023-2024 | Edarbi, Edarbi |
| Bayer Healthcare Pharmaceuticals INC. | $122.62 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $101.61 | 2019-2024 | Farxiga |
| Zoll Circulation INC | $67.45 | 2022-2023 | Therox Ds2 Console, Downstream Cartridge, Catheter |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $60.00 | 2019 | |
| Kestra Medical Technology Services, INC. | $49.47 | 2024-2025 | Assure Wcd |
| Scpharmaceuticals INC. | $43.60 | 2023-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $38.14 | 2019 | |
| Arbor Pharmaceuticals, INC. | $33.19 | 2020-2021 | |
| Novo Nordisk INC | $31.86 | 2025 | Ozempic |
| Gilead Sciences, INC. | $29.36 | 2019 | |
| Alnylam Pharmaceuticals INC. | $26.24 | 2023 | Onpattro |
| Cardiva Medical, INC. | $25.86 | 2020-2021 | |
| Kiniksa Pharmaceuticals, LTD. | $20.69 | 2023 | Arcalyst |
| Boston Scientific Corporation | $20.66 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $17.83 | 2023 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stratego Castanes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.